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number of comorbidities were all significant predictors
accounting for 26% of variance in costs. Number of co-
morbidities was the only variable significantly associated
with the cost of antibiotics. CONCLUSIONS: Appropri-
ate empirical antibiotic treatment of patients with culture
positive intra-abdominal infection is strongly associated
with length of stay and hospital costs.
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OBJECTIVES: Historically, complication rates following
colorectal surgery were stratified by disease process, type
of operation, or anesthesia risk derived after an intensive
review of the medical record. Newer computer applica-
tions purport to shorten this process and predict the
probability of postoperative complications by distin-
guishing them from comorbidities that are co-mingled on
uniform discharge codes. We analyzed CaduCIS software
(CareScience, Inc., Philadelphia, PA) which uses dis-
charge codes to see if its predictions of comorbidity and
complications accurately track the medical record.
METHODS: Two-hundred and seventy patients were an-
alyzed using principal and secondary diagnoses coded on
discharge. Coding inaccuracies of clinical occurrences
were identified by physician review of each medical
record. The actual incidences of 17 common preoperative
comorbidities and 11 postoperative complications were
compared to computerized predictions by applying stan-
dard statistical tests. RESULTS: The overall incidence of
complications obtained by physician (actual) review was
47%, compared to 46% by computer. The computerized
predicted distribution of comorbidities was similar to the
actual occurrences in 15 of 17 categories. Analysis
showed a statistical difference between the computer-pre-
dicted and “actual” complication rates in 5 of the 11 cat-
egories; however these differences (underestimates) were
due to charting and coding inaccuracies, not to comput-
erized errors. The most common preoperative comorbidi-
ties and complications were cardiopulmonary (47% and
28%, respectively). CONCLUSIONS: The computer-sys-
tem’s accurate measurement of the overall complication
rate supports the claim that aggregate complication esti-
mates derived from readily available administrative data
are sufficient for across-the-board comparisons among
hospitals. The computerized system can generate such
measurements in a fraction of the time is takes to manu-
ally review the medical records. As uniform discharge
coding of co-mingled comorbidity and complications are
increasingly used to rapidly compute surgical outcomes,
colon and rectal surgeons need to ensure compatibility of
the actual and coded medical record.
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OBJECTIVES: Infliximab (Remicade) (I) 5mg/kg is effec-
tive to control refractory Crohn’s disease in 81% and to
improve fistulas in 68% of patients, thus greatly improv-
ing quality of life (QoL). The objective of this study was
to calculate the direct costs and savings generated by I to
achieve this improvement of QoL. METHODS: This mir-
ror-image study was carried out in 48 patients, of which
22 had fistulas, all responding to therapy. Patients were
followed for 6 to 24 months prior and 6 to 24 months af-
ter I. All direct costs to the Belgian public payer were re-
corded separately for every 6 month time period before
and after I, in order to control for a bias due to changed
management regardless of I. The cost of I was calculated
separately. IBDQ scores were recorded before and after I
for each period. RESULTS: There was an important
build up of costs in each period before I: 2–1.5y: 1,002
(459) Euro; 1.5–1.0y: 1,486 (459) Euro; 1.0–0.5:
2,114 (391) Euro; 0.5–0: 2,427 (302) Euro. After I
there was a sharp decrease of the cost of care (excluding
the cost of I) to 1,760 (239) Euro (00.5y) and 1,380
(264) Euro (0.51.0y). The decrease was statistically
significant (p0.016). The average cost of I in the first
six months was 4,850 (327) Euro and in the second six
months 1,300 (280) Euro. The IBDQ increased from
147.8 (SE 8.4) to 187.8 (SE 7.0). The total direct cost of
care after I, adjusted for the non-responders, was calcu-
lated to be 17.0 Euro per day of normalised QoL. CON-
CLUSIONS: Although the cost of infliximab is substan-
tial, the total direct cost to produce a normal QoL in the
entire year after therapy is quite acceptable, providing
that patients not responding are not further treated.
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Health-related quality of life (HRQoL) research suggests
that, due to unique characteristics of a disease state, dis-
ease specific tools are better discriminators of health sta-
tus than generic tools. OBJECTIVE: To compare generic
(SF-12) versus disease specific (SIBDQ) quality of life
tools in a cohort of patients receiving treatment for
Crohn’s Disease (CD). METHODS: Structural Equation
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Modeling techniques were used to evaluate the effective-
ness of the SF-12 and the SIBDQ for evaluating health
status patients with CD. A cohort of 151 patients with
CD receiving drug therapy was administered both instru-
ments via telephone survey. RESULTS: The variance ex-
plained by the SIBDQ in this population was 11.6%
while the SF-12 explained 55.7%. Adapted models of
both the SIBDQ and SF-12 resulted in explained variance
of 54.8% and 84.1%, respectively. CONCLUSIONS:
Given these results, the generic HRQoL tool was signifi-
cantly better than the disease specific tool at measuring
and accounting for health status in this population. Pa-
tients with moderate or severe CD have previously been
shown to have differing clinical response to therapy
based upon disease severity, whereby patients with more
severe disease have better response. Due to these possible
unique clinical outcomes of newer medications such as
infliximab, the effectiveness of disease specific tools may
be compromised since improving therapies may affect
HRQoL in a different manner than therapies previously
available. Other innovative therapies, such as biologic re-
sponse modifiers for rheumatoid arthritis, may have simi-
lar findings related to HRQoL measurement. This poten-
tial problem with HRQoL measurement is likely to
increase as biopharmaceutical and pharmacogenomic re-
search increases the number and rate of new product ap-
provals. These findings have important implications re-
lated to measurement of HRQoL in clinical trials and
pharmacoeconomic evaluation of medications. This sug-
gests a need for careful reevaluation of disease specific
tools given the clinical effects of newer therapies.
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OBJECTIVE: Cold symptoms are both common and
costly. The effectiveness of zinc lozenges in reducing the
duration of common cold symptoms has been investi-
gated in several studies with discrepant results. We there-
fore performed a meta-analysis in an attempt to clarify
these discrepancies and determine the overall effective-
ness of zinc lozenges in the treatment of the common
cold. METHODS: A computerized search of the MED-
LINE database from January 1966 to December 2000
was performed to identify randomized controlled trials
comparing zinc lozenges to placebo for the common cold.
Data were systematically abstracted. The outcome as-
sessed was the duration of cold symptoms. Quantitative
pooling was undertaken using the Dersimonian and Laird
random-effects model. RESULTS: Five studies met the in-
clusion criteria and provided sufficient information to
calculate the mean duration of cold symptoms. A total of
562 subjects were included in these trials: 283 in the zinc
group and 279 in the placebo group. The summary mean
duration of cold symptoms in the zinc group was 2.25
days less than that in the placebo group (95% confidence
interval [CI], 1.07–3.43). However, there was evidence of
statistical heterogeneity among studies (P  0.003). In a
subgroup analysis, we found that there were two sets of
homogeneous studies with different magnitudes of reduc-
tion: 3.6 days (95% CI: 2.77,4.43) and 1.32 days (95%
CI: 0.52,2.13). CONCLUSIONS: Zinc lozenges appear
to be an effective treatment for reducing the duration of
cold symptoms. However, further analyses are required
to explore the sources of heterogeneity. A formal cost-
effectiveness analysis may be necessary to determine
whether this intervention is economical.
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OBJECTIVES: The incidence and costs associated with
the rehospitalization of heart transplant patients for the
treatment of CMV infection have not been well docu-
mented. Two adult heart transplant centers participated
in a Transplant Infection Cost Analysis program that was
implemented in several centers covering different solid
organ programs. METHODS: A retrospective chart re-
view of all patients rehospitalized within two years post-
transplant identified the number of such readmissions,
hospital costs and charges for the CMV associated read-
mission, and the length of stay. Data were pooled for
analysis. All dollar amounts were standardized to 1997
dollars using the Medical Care component of the Con-
sumer Price Index. RESULTS: Between 1994 and 1996,
the two hospitals performed a total of 163 heart trans-
plants. There were a total of 34 readmissions (21%) to
these hospitals associated with a CMV infection. Total
direct hospital costs were $740,220 (average $21,771
and range $1,324–$349,224). Total related charges were
$1,431,793 (average $42,111 and range $2,323–
$698,447). Total days of inpatient care for CMV infec-
tion were 371 days (average 10.9 and range 2–95) at an
average cost per day of $1,997. CONCLUSIONS: Data
from two heart transplant centers demonstrate that CMV
infection caused significant readmissions. Use of hospital
resources to treat CMV infection one to two years post-
transplant was substantial. Total cost of CMV was not
captured: readmission to other hospitals, outpatient costs,
physician costs, mortality and lost productivity should be
included for a complete assessment of the economic bur-
den of CMV infection.
